MX2022015327A - Compuestos y metodos para el tratamiento de trastornos oculares. - Google Patents
Compuestos y metodos para el tratamiento de trastornos oculares.Info
- Publication number
- MX2022015327A MX2022015327A MX2022015327A MX2022015327A MX2022015327A MX 2022015327 A MX2022015327 A MX 2022015327A MX 2022015327 A MX2022015327 A MX 2022015327A MX 2022015327 A MX2022015327 A MX 2022015327A MX 2022015327 A MX2022015327 A MX 2022015327A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- compounds
- treatment
- eye disorders
- reducing
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 208000030533 eye disease Diseases 0.000 title 1
- 201000004569 Blindness Diseases 0.000 abstract 2
- XMGGYBQTSVRRCF-VQHVLOKHSA-N 2-[[(e)-3-[4-(difluoromethoxy)-3-methoxyphenyl]prop-2-enoyl]amino]benzoic acid Chemical compound C1=C(OC(F)F)C(OC)=CC(\C=C\C(=O)NC=2C(=CC=CC=2)C(O)=O)=C1 XMGGYBQTSVRRCF-VQHVLOKHSA-N 0.000 abstract 1
- 206010012689 Diabetic retinopathy Diseases 0.000 abstract 1
- 208000002158 Proliferative Vitreoretinopathy Diseases 0.000 abstract 1
- 206010038934 Retinopathy proliferative Diseases 0.000 abstract 1
- 208000018769 loss of vision Diseases 0.000 abstract 1
- 231100000864 loss of vision Toxicity 0.000 abstract 1
- 208000021971 neovascular inflammatory vitreoretinopathy Diseases 0.000 abstract 1
- 230000006785 proliferative vitreoretinopathy Effects 0.000 abstract 1
- 230000004393 visual impairment Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
Abstract
En la presente se describen métodos de administración de ácido (E)-2-[[3-metoxi-4-(difluorometoxi)fenil-1-oxo-2-propenil]amino]b enzoico a un sujeto, que implican regímenes particulares de administración para prevenir, tratar, reducir la gravedad y/o reducir la probabilidad de recurrencia de condiciones oculares tal como retinopatía diabética y vitreorretinopatía proliferativa. Estas condiciones oculares pueden tener consecuencias graves, incluida la pérdida de la visión, y en algunos casos, ceguera.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2020901856A AU2020901856A0 (en) | 2020-06-05 | Compounds and Methods for the Treatment of Eye Disorders | |
| AU2020901858A AU2020901858A0 (en) | 2020-06-05 | Compounds and Methods for the Treatment of Eye Disorders | |
| PCT/US2021/035749 WO2021247900A1 (en) | 2020-06-05 | 2021-06-03 | Compounds and methods for the treatment of eye disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022015327A true MX2022015327A (es) | 2023-02-22 |
Family
ID=78829970
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022015327A MX2022015327A (es) | 2020-06-05 | 2021-06-03 | Compuestos y metodos para el tratamiento de trastornos oculares. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230270703A1 (es) |
| EP (1) | EP4161527A4 (es) |
| JP (1) | JP2023529845A (es) |
| KR (1) | KR20230024331A (es) |
| CN (1) | CN116033901A (es) |
| AU (1) | AU2021284380A1 (es) |
| BR (1) | BR112022024728A2 (es) |
| CA (1) | CA3185849A1 (es) |
| IL (1) | IL298733A (es) |
| MX (1) | MX2022015327A (es) |
| WO (2) | WO2021247900A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2022238294A1 (en) * | 2021-03-17 | 2023-10-05 | Occurx Pty Ltd | Compounds for the treatment of disorders and salts and polymorphs thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL132391A0 (en) * | 1997-04-18 | 2001-03-19 | Kissei Pharmaceutical | Preventives or remedies for diseases effecting excessive proliferation or retinal pigment eptihelial cells |
| AU2002366641A1 (en) * | 2001-12-11 | 2003-06-23 | Fibrogen, Inc. | Methods for inhibiting ocular processes |
| KR101471732B1 (ko) * | 2003-08-27 | 2014-12-16 | 옵쏘테크 코포레이션 | 안구의 혈관신생성 장애를 치료하기 위한 조합 치료법 |
| US8168584B2 (en) * | 2005-10-08 | 2012-05-01 | Potentia Pharmaceuticals, Inc. | Methods of treating age-related macular degeneration by compstatin and analogs thereof |
| EP3167886B1 (en) * | 2007-10-19 | 2020-08-05 | Novartis AG | Compositions and methods for treatment of macular edema |
| WO2010137681A1 (ja) * | 2009-05-29 | 2010-12-02 | 参天製薬株式会社 | トラニラストを含有する網膜疾患の予防または治療剤、網膜疾患の予防または治療方法、トラニラストまたはその医薬的に許容される塩、ならびにその使用 |
| US9839640B2 (en) * | 2010-11-24 | 2017-12-12 | Occurx Pty Ltd | Methods of treating eye diseases associated with inflammation and vascular proliferation |
| US10780070B2 (en) * | 2013-10-18 | 2020-09-22 | The Schepens Eye Research Institute, Inc. | Alpha-aminoadipate for treatment of vision loss and restoring sight |
-
2021
- 2021-06-03 MX MX2022015327A patent/MX2022015327A/es unknown
- 2021-06-03 CA CA3185849A patent/CA3185849A1/en active Pending
- 2021-06-03 BR BR112022024728A patent/BR112022024728A2/pt unknown
- 2021-06-03 EP EP21818477.8A patent/EP4161527A4/en active Pending
- 2021-06-03 WO PCT/US2021/035749 patent/WO2021247900A1/en unknown
- 2021-06-03 AU AU2021284380A patent/AU2021284380A1/en active Pending
- 2021-06-03 CN CN202180056862.4A patent/CN116033901A/zh active Pending
- 2021-06-03 US US18/007,714 patent/US20230270703A1/en active Pending
- 2021-06-03 JP JP2022574480A patent/JP2023529845A/ja active Pending
- 2021-06-03 WO PCT/US2021/035750 patent/WO2021247901A1/en active Application Filing
- 2021-06-03 KR KR1020237000380A patent/KR20230024331A/ko active Search and Examination
- 2021-06-03 IL IL298733A patent/IL298733A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021284380A1 (en) | 2023-01-19 |
| WO2021247900A1 (en) | 2021-12-09 |
| CA3185849A1 (en) | 2021-12-09 |
| EP4161527A1 (en) | 2023-04-12 |
| IL298733A (en) | 2023-02-01 |
| EP4161527A4 (en) | 2024-06-26 |
| US20230270703A1 (en) | 2023-08-31 |
| BR112022024728A2 (pt) | 2023-03-07 |
| WO2021247901A1 (en) | 2021-12-09 |
| JP2023529845A (ja) | 2023-07-12 |
| CN116033901A (zh) | 2023-04-28 |
| KR20230024331A (ko) | 2023-02-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sloot et al. | Effective corneal collagen crosslinking in advanced cases of progressive keratoconus | |
| Sampat et al. | Complications of intravitreal injections | |
| Arcieri et al. | Efficacy and safety of intravitreal bevacizumab in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation: 2‐year follow‐up | |
| PH12015502587A1 (en) | Opthalmic nanoemulsion composition containing cyclosporine and method for preparing same | |
| Sisto et al. | The role of antimetabolites in filtration surgery for neovascular glaucoma: intermediate‐term follow‐up | |
| US20070254914A1 (en) | Low-concentration atropine solution for preventing myopia progression and preparing method thereof | |
| CN114306575A (zh) | 具有小的活动性脉络膜新生血管病变的年龄相关性黄斑变性的治疗 | |
| MX2022015327A (es) | Compuestos y metodos para el tratamiento de trastornos oculares. | |
| MX2022005063A (es) | Tratamiento de enfermedades oculares con antagonistas de receptor de endotelina. | |
| Ma et al. | Bilateral lateral rectus muscle recession for the convergence insufficiency type of intermittent exotropia | |
| Beckman | Epithelium-on corneal collagen cross-linking with hypotonic riboflavin solution in progressive keratoconus | |
| Ekdawi et al. | Intravitreal triamcinolone and bevacizumab combination therapy for macular edema due to central retinal vein occlusion refractory to either treatment alone | |
| Ji et al. | Therapeutic effect of intravitreal injections of ranibizumab for the treatment of macular choroidal neovascularization caused by pathological myopia | |
| Varman et al. | Safety and efficacy of low-energy small incision lenticule extraction for the correction of myopia and myopic astigmatism: A retrospective analysis | |
| Khan et al. | Preliminary results of UV? A riboflavin crosslinking in progressive cases of keratoconus, in Pakistani population | |
| Hasani et al. | Trans-epithelial photorefractive keratectomy in the treatment of myopia, hyperopia and astigmatism: five-year results | |
| Averbukh et al. | Diabetic macular edema: towards therapy aimed at the underlying pathogenic mechanisms | |
| Cagini et al. | Penetration of Prulifloxacin in human aqueous humour following oral administration | |
| Lim et al. | 4 Advances in Corneal Crosslinking | |
| Amin et al. | Transepitheial High Fluence Crossliniking for Keratoconus | |
| Mohamed et al. | Laser In Situ Keratomileusis Retreatment with Wavefront-Optimized Technique after Primary Wavefront-Guided LASIK: Proof of Concept | |
| Alkharashi et al. | Corneal cross-linking | |
| Paduca | Consecutive exotropia after convergent strabismus surgery—Surgical treatment | |
| Wen-hong et al. | Surgical methods and effect of the children's consecutive esotropia | |
| Fiebai et al. | Intravitreal Anti Vascular Endothelial Growth Factor Agents in the Management of Retinal Diseases: An Audit: Vitreo-Retina |